Mantle cell lymphoma (MCL) is an aggressive and mostly incurable B-cell malignancy with frequent relapses after an initial response to standard chemotherapy. Therefore, novel therapies are urgently required to improve MCL clinical outcomes. In this study, MCL cell lines were treated with pterostilbene (PTE), a non-toxic natural phenolic compound primarily found in blueberries. The antitumor activity of PTE was examined by using the Cell Counting Kit-8, apoptosis assays, cell cycle analysis, JC-1 mitochondrial membrane potential assay, western blot analysis, and tumor xenograft models. PTE treatment induced a dose-dependent inhibition of cell proliferation, including the induction of cell apoptosis and cell cycle arrest at the G0/G1 phase. Moreover, the PI3K/Akt/mTOR pathway was downregulated after PTE treatment, which might account for the anti-MCL effects of PTE. Synergistic cytotoxicity was also observed, both in MCL cells and in xenograft mouse models, when PTE was administered in combination with bortezomib (BTZ). The antitumor effects of PTE shown in our study provide an innovative option for MCL patients with poor responses to standardized therapy. It is noteworthy that the treatment combining PTE with BTZ warrants clinical investigation, which may offer an alternative and effective MCL treatment in the future.
Introduction
Mantle cell lymphoma (MCL), accounting for 5%-8% of nonHodgkin's lymphoma cases, is an aggressive lymphoid malignancy characterized by a relatively poor clinical course and prognosis [1, 2] . Current first-line combination chemotherapies, intensive chemoimmunotherapy, as well as stem cell transplantation have improved the outcome for MCL patients [3] . Although patients receiving these regimens can often reach high initial response rates, unfortunately, relapse commonly occurs, leading to a median survival period as short as only 5-7 years for most patients [4, 5] . Thus, non-toxic and well-tolerated agents that can expand the length of remission are needed. Meanwhile, the development of effective agents for relapsed/refractory patients is also equally necessary and important.
Pterostilbene (trans-3, 5-dimethoxy-4-hydroxystilbene; PTE), chemically classified as a stilbene, is produced naturally by a variety of plants and predominantly by blueberries as well as by some types of grapes. PTE has been previously reported to be an effective chemopreventive agent against multiple cancers by several research groups [6] [7] [8] [9] . PTE has a similar structure and pharmacological properties as resveratrol, a well-known compound with antioxidant, anti-aging, and anti-inflammatory activities. Nevertheless, PTE has better pharmacokinetic characteristics (i.e. more lipophilic, higher oral absorption, and greater potential for cellular uptake) than resveratrol [8, 10] . Previous animal studies have shown that PTE exhibits 80% bioavailability compared to only 20% by resveratrol, which favors it as a promising therapeutic agent [11] . The mechanisms underlying PTE's activity against malignancies include the induction of cell cycle arrest, apoptosis, autophagy, and necrosis in both solid (such as liver, colon, prostate, and breast cancers) [12] [13] [14] [15] and non-solid tumors (such as acute/chronic myelogenous leukemia and lymphoblastic leukemia) [16, 17] . These findings indicate that PTE can inhibit the growth of tumors, both in vitro and in vivo, and may provide an opportunity to achieve effective clinical application in addition to its significant bioavailability.
However, to the best of our knowledge, there are few studies that have tested the effects of PTE against non-Hodgkin's lymphoma, especially MCL. We hypothesized that PTE may act against tumor growth in MCL cell lines based on our previous findings [9, 16] . Therefore, the present study was designed to determine the potential antitumor effects of PTE against MCL, as well as to explore the underlying mechanisms. Furthermore, we also sought to investigate the anti-MCL efficacy of PTE when combined with bortezomib (BTZ).
Materials and Methods
Reagents PTE (purity >98%; J & K Chemical Ltd., Beijing, China) was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St Louis, USA) at a concentration of 100 mM and stored at -20°C until use. The Cell Counting Kit-8 (CCK-8) was purchased from Yeasen (Shanghai, China). The Mitochondrial Membrane Potential Detection Kit JC-1 was purchased from Beyotime Institute of Biotechnology (Shanghai, China). The primary antibodies against PI3K (1:1000), phosphor (p)-PI3K (1:1000), cleaved caspase-3 (1:1000), cleaved caspase-8 (1:1000), Bcl-2 (1:3000), p70S6K (1:1000), p-p70S6K (1:1000), Akt (1:2000), p-Akt (473; 1:2000), and mTOR (1:3000) were from Cell Signaling Technology (Beverly, USA). Anti-Bax (1:1000), Bcl-XL (1:1000), caspase-9 (1:1000), CDK4 (1:1000), CDK6 (1:1000), Cyclin D1 (1:1000), and p-mTOR (1:3000) antibodies were from Abcam (Cambridge, UK). Z-VAD-FMK was provided by Selleck Chemicals (Houston, USA). Annexin V-FITC and propidium iodide (PI) detection kit was purchased from BD Pharmingen (San Diego, USA).
Cell culture
The human MCL cell lines JeKo-1 and Granta-519 were purchased from the American Type Culture Collection (Manassas, USA). Mino, Z-138, and Rec-1 cell lines were kindly provided by Dr Xue Han of Tianjin Medical University Cancer Hospital (Tianjin, China). Cells were cultured in RPMI-1640 medium (Gibco, Carlsbad, USA), supplemented with 10% fetal bovine serum (FBS; Gibco), 100 IU/ml penicillin, and 100 μg/ml streptomycin (Gibco), and incubated in a humidified atmosphere of 5% CO 2 at 37°C. The culture medium was changed every other day. 
Growth inhibition assay

Analysis of cell apoptosis
Cell apoptosis assessments were performed using the doublestaining method of the Annexin V/PI apoptosis detection kit (BD Pharmingen, San Diego, USA). According to the manufacturer's instructions, MCL cells (2 × 10 5 cells/ml) were seeded into 24-well plates and treated with PTE (0, 20, 40, or 80 μM) for 48 h. The cells were harvested, washed with PBS, stained with Annexin V-FITC/PI, and analyzed using a BD FASCCanto II flow cytometer (BD Biosciences, San Diego, USA). In this study, apoptotic cells included early (Annexin V positive and PI negative) and late (both Annexin V and PI positive) apoptotic cells.
JC-1 assay
The mitochondrial membrane potential was detected by using the JC-1 kit (Beyotime Institute of Biotechnology). JeKo-1 and Granta-519 cells (2 × 
Western blot analysis
JeKo-1 and Granta-519 cells were lysed with lysis buffer (100 mM Tris-HCl, pH 6.8, 4% SDS and 20% glycerol) after treatment with different concentrations of PTE. Total cell lysates (30 μg per lane) were separated by 8%-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were transferred onto a nitrocellulose or polyvinylidene difluoride membrane, which was blocked with 5% BSA or 5% skim milk for 1 h at room temperature, and incubated with primary antibodies overnight at 4°C. Before and after being incubated with the appropriate secondary antibodies (anti-rabbit or anti-mouse IgG, LI-COR; Lincoln, USA), membranes were washed three times with Tween 20-PBS. Finally, the fluorescence was measured by the Odyssey two-color infrared laser imaging system (LI-COR).
Tumor xenograft models
Four to six-week-old female NOD/SCID mice were purchased from Shanghai Laboratory Animal Center (Shanghai, China) and housed in a standard animal laboratory and provided standard food and water ad libitum. Human JeKo-1 cells (1 × 10 8 cells/ml) were suspended in serum-free culture medium and each of the NOD/SCID mice was subcutaneously injected with 100 μl of cell suspension into the right upper flank region. When tumors were measurable, the mice were randomly divided into four groups (n = 4/group) as follows: control group treated with 0.05% DMSO (vehicle), BTZ group treated with BTZ at 0.5 mg/kg, PTE group treated with PTE at 50 mg/kg, PTE and BTZ combination group treated with PTE at 50 mg/kg and BTZ at 0.5 mg/kg. BTZ (diluted with saline) was administered intraperitoneally every 3 days and PTE (diluted with DMSO in saline) was administered intraperitoneally every day. 
Immunohistochemical analysis
The in vivo expression level of candidate target protein mTOR was detected by immunohistochemical (IHC) analysis. Tumor samples of per group in xenograft animal experiment were analyzed after 15 days of treatment. The paraffin-embedded tumor samples were dewaxed, infiltrated in citrate buffer (0.01 M, pH 6.0) and then heated in a microwave for 5 min to carry out antigen retrieval. Next, slides were blocked with 3% hydrogen peroxide for 10 min. Before and after incubation with primary antibody against p-mTOR (1:50; Santa Cruz, Santa Cruz, USA) overnight at 4°C, the sections were washed with PBS three times. After that, the peroxidaselabeled goat anti-mouse secondary antibody (1:100; Jackson, West Grove, USA) was applied at room temperature for 30 min. Finally, peroxidase substrate 3,3-′diaminobenzidine tetrahydrochloride (DAB) was added for staining. All slides were counterstained with hematoxylin and observed by light microscopy.
Terminal deoxynucleotidyl transferase dUTP nick-end labeling assay
The terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay was carried out according to the manufacturer's instructions (DeadEnd System; Promega, Madison, USA) to determine apoptosis in xenograft animal experiment tumor tissues. Briefly, 5-μm paraffin-embedded sections were treated with 20 μg/ ml proteinase K. DNA was end-labeled using Biotinylated Nucleotide Mix in TdT buffer at 37°C for 1 h. Then, DAB was added for staining and DNA strand breaks were visualized. Apoptotic cells were quantified by detecting the percentage of apoptotic cells per field.
Statistical analysis
Data are expressed as the mean ± standard deviation (SD (Fig. 1) .
PTE treatment results in apoptosis and mitochondrial depolarization in MCL cell lines
To elucidate the mechanism of PTE-induced cytotoxicity, Annexin V/PI double staining was performed in MCL cell lines treated with PTE. Consistent with the CCK-8 assay results, Annexin V/PI double-staining results indicated that PTE treatment increased cell apoptosis in a dose-dependent manner ( Fig. 2A) . As determined by the JC-1 detection assay, the loss of mitochondrial membrane potential (MMP) indicates the early stage of intrinsic apoptosis [18] . PTE treatment resulted in the loss of MMP in a dose-dependent manner (Fig. 2B) .
PTE treatment enhances caspase activation
To determine the mechanism of PTE-induced apoptosis in MCL cells, we measured the protein levels associated with the apoptosis pathway by western blot analysis. The levels of cleaved caspase-3, caspase-8, caspase-9, and Bax in JeKo-1 and Granta-519 cells were increased after PTE treatments, while Bcl-2 and Bcl-XL levels were decreased (Fig. 3A) . To confirm the role of the caspase pathway in PTE-induced apoptosis, a pan-caspase inhibitor, Z-VAD-FMK, was used. As shown in Fig. 3B , Z-VAD-FMK treatment partially blocked PTE-induced cell apoptosis, as determined by Annexin-V/PI double staining. These data demonstrated that PTE triggered caspasedependent apoptosis in MCL cells.
PTE treatment results in cell cycle arrest in the G0/G1 phase Because both cell apoptosis and cell cycle are important for cell proliferation, the effect of PTE on the cell cycle was further determined by flow cytometry. An obvious predominance of cells were arrested in G0/G1 phase as shown by DNA content analyses after treatment with PTE for 6 h (Fig. 4A,B) . To investigate the underlying molecular mechanisms of PTE-induced G0/G1 phase arrest, cyclin-dependent kinase proteins were analyzed by western blot analysis. Treatment with PTE down-regulated protein expression levels of CDK4, CDK6, and Cyclin D1 in a dose-dependent manner (Fig. 4C ).
PI3K/Akt/mTOR pathway inactivation is associated with PTE-mediated apoptosis
We further analyzed several pathways known to be important for MCL cell proliferation and survival. JeKo-1 and Granta-519 cells were treated with PTE (0, 20, and 40 μM) for 48 h, and cell lysates were collected for western blot analysis. The levels of p-PI3K, p-Akt, p-mTOR, and p-p70S6K were significantly lowered after PTE treatment, while the expression levels of total PI3K, Akt, mTOR, and p70S6K were not changed (Fig. 5A) . Together, these data showed that PTE inhibited the PI3K/Akt/mTOR pathway, which may be involved in the antiproliferative mechanism of PTE in MCL cells.
Synergistic effects of PTE in combination with several drugs frequently used for hematological tumor treatments
MCL is an aggressive and mostly incurable B-cell malignancy with frequent relapses after an initial response to standard chemotherapy. Therefore, single-agent therapy often does not achieve satisfactory clinical efficacy. In this study, we combined PTE treatment with drugs frequently used to treat hematological tumors. PTE showed synergistic effects with several drugs, especially with dexamethasone (DEX) and BTZ. Median dose effect analyses showed that the combination of PTE and BTZ successfully induced synergistic cytotoxicity (CI < 1.0) in JeKo-1 and Granta-519 cells (Fig. 5B) , as did the combination of PTE and DEX with a CI < 1.0 (Fig. 5C) . CI = 1 represents additive effect, CI < 1 represents synergism, and CI > 1 represents antagonism [19] .
PTE and BTZ have synergistic effects in vivo in MCL xenograft models
To determine whether the results of in vitro experiments could also be achieved in vivo, we examined the effects of PTE in human JeKo-1 animal xenograft models. Mice were randomly divided into four groups (n = 4/group) as follows: control group with 0.05% DMSO; BTZ group with BTZ at 0.5 mg/kg; PTE group with PTE at 50 mg/kg; and PTE and BTZ combination group with PTE at 50 mg/ kg and BTZ at 0.5 mg/kg. The results showed that tumor growth was significantly inhibited in PTE and BTZ combination groups compared to that in the control group (P < 0.001) after 15 days of treatment (Fig. 6A,B) . BTZ or PTE single treatments significantly inhibited tumor growth compared to the control treatment (P < 0.01). When compared to either single-agent group, the combination group showed higher intensity of tumor growth inhibition (P < 0.05 vs. single PTE or single BTZ group). In addition, hematoxylin and eosin (H&E) staining revealed increased necrosis in the PTE treatment groups, especially in PTE and BTZ combination groups (Fig.  6D) . In addition, the TUNEL assay showed that PTE treatment resulted in increased cell apoptosis compared to that observed in the control group (Fig. 6D) . Furthermore, IHC staining showed that the expression of p-mTOR was downregulated after PTE treatment (Fig.  6D) , especially in PTE and BTZ combination groups. Analyses of mouse body weights demonstrated no significant differences between groups over the course of treatment (Fig. 6C) . These results suggest that PTE may be a promising agent for MCL treatment.
Discussion
PTE, a natural dimethylated analog of resveratrol, has recently attracted attention for its promising chemopreventive and chemotherapeutic properties [20] [21] [22] [23] . In addition, PTE exhibits strong anti-invasive and anti-metastatic effects against TPA-mediated metastasis via initially downregulating the expression levels of PKC, EGF, and VEGF, as well as by consequently blocking signaling pathways such as MAPK and PI3K/Akt and transcription factors such as NF-κB, AP-1, and matrix metalloproteinase-9 (MMP-9) [24] . The mammalian target of rapamycin (mTOR), a downstream serinethreonine kinase of Akt, forms complexes with mTORC1 (mTORRaptor) and mTORC2 (mTOR-Rictor), which have been reported to be able to enhance tumor proliferation and facilitate to escape from apoptosis, as well as to cause frequent relapses in MCL therapy [25] [26] [27] [28] . In this study, we found that no obvious toxicity such as body weight loss was observed in the MCL xenograft mouse model. PTE successfully inhibited the expression of mTOR and exerted potent anti-MCL activity. The anti-MCL activities of PTE were clearly evident not only by the dose-and time-dependent cytotoxic effects on human MCL cell lines but also by the induction of G0/G1 phase arrest via downregulating the expression levels of CDK4, CDK6, and Cyclin D1. Our data indicated that PTE triggered apoptosis by elevating the expression of cleaved caspase-3, caspase-8, and caspase-9, which was attenuated by the addition of a pan-caspase inhibitor. Caspase-8 and caspase-9 are two key proteins activated in the extrinsic and intrinsic apoptotic pathways, respectively, both of which can result in the downstream cleavage of caspase-3 [29] . We further investigated the MMP which is an indicator of mitochondrial membrane permeability and is altered in early stages of intrinsic apoptosis followed by subsequent activation of caspase-9 [30] . The loss of MMP observed in this study indicated that PTE could induce cell apoptosis via the intrinsic apoptotic pathway. Furthermore, the observed proapoptotic effects of PTE included upregulation of the pro-apoptotic mitochondrial-derived protein, Bax, and the downregulation of antiapoptotic mitochondrial derived proteins, Bcl-2 and Bcl-XL. Similar results have also been reported in other cancer cell lines [31] , which suggested that the apoptosis of MCL cells induced by PTE was caspase-dependent and involved the activation of both intrinsic and extrinsic apoptotic pathways.
In order to investigate the molecular anti-proliferative mechanisms of PTE in MCL, several signaling pathways contributing to MCL pathogenesis, including the constitutively activated PI3K/Akt/ mTOR pathway that promotes tumor proliferation and survival, were explored in JeKo-1 and Granta-519 cells treated with PTE. Agents targeting these pathways may provide new therapeutic options. Previous studies have shown that Akt is a serine-threonine kinase that regulates cell survival and proliferation [32] [33] [34] [35] . Located upstream of Akt, the PI3 lipid kinase is a key point for the survival of B-cells because PI3Ks generate phosphatidyl-inositol-3,4,-5-phosphate, the second messenger, to recruit and activate PDK and Akt kinases. The constitutive activation of Akt [27, 28, 36] and PI3Ks [37, 38] has also been reported to be essential to the pathogenesis and survival of MCL cells. Akt activation also leads to phosphorylation and activation of mTOR, a kinase that stimulates protein synthesis and cell proliferation. In addition, it has been reported that BTZ resistance in MCL is associated with activation of PI3K and its downstream mTOR/p70S6K pathways, suggesting that suppression of PI3K and mTOR might be a potential means to overcome BTZ resistance [39] . Similar results also showed that treatments combining a PI3K inhibitor (LY294002) with an mTOR inhibitor (rapamycin) also reduced BTZ-resistant MCL cell viability [40] .
In this study, results of western blot analysis showed that the expression of p-PI3K/p-Akt/p-mTOR/p-p70S6K was suppressed in PTE-treated MCL cells. In addition, immunohistochemical analysis of tumor samples from the xenograft mouse model showed similar results in that p-mTOR was decreased compared to that in the control group. Together with the apoptosis induced by PTE, our results indicated that suppression of the PI3K/Akt/mTOR pathway played a pivotal role in PTE-induced apoptosis of MCL cells via a caspasedependent mechanism. The suppression of mTOR induced by PTE may simultaneously target both mTORC1 and mTORC2, since our data showed the expression levels of both p70S6K and Akt were suppressed [41, 42] , making PTE more effective than inhibitors of the mTORC1 complex such as rapamycin and its analogs (i.e. rapalogs).
Although MCL initially responds to frontline chemotherapy, it remains incurable with conventional therapeutic regimens. Therefore, we assessed whether PTE could be used as a part of a combination therapy and found that treatment with both PTE and BTZ resulted in a synergistic anti-proliferative effect on MCL cells as well as in a xenograft mouse model. The same was found with the combination of PTE and DEX in further investigations we conducted within other candidates. This synergistic effect of PTE with BTZ might be reasonably explained by the downregulation of PI3K/ AKT/mTOR shown in this study. Despite recent advances in the treatment of MCL with BTZ, not all patients respond well and resistance often occurs after initial treatment. Based on our present results, combined PTE-BTZ therapy may be a promising strategy to further improve clinical outcomes in MCL patients.
In summary, our present study showed the potent in vitro and in vivo anti-cancer activities of PTE in MCL. In addition to the inhibition of proliferation by itself, PTE could remarkably enhance the anti-MCL activity of BTZ in MCL cells and in the xenograft mouse model when combined with BTZ, which may shed light on the potential application of PTE and BTZ combination therapy for the treatment of MCL patients, especially those with refractory and relapsed disease. Nevertheless, the more detailed mechanisms of PTE's antimalignancy efficacy in MCL will still require further investigation before its clinical application.
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